NeoGenomics Inc. shared a strong financial outlook for 2025 and beyond. The Fort Myers-based cancer testing and research lab ...

NeoGenomics' Chris Smith will retire as CEO and board member, effective April 1, 2025. Tony Zook will assume the role of CEO ...

Fort Myers-based cancer lab NeoGenomics is getting a new CEO. Tony Zook, an independent board member, will assume the role.

Shares of NeoGenomics, Inc. (NASDAQ: NEO) are, after the company announced that CEO Chris Smith will retire effective April 1 ...

NeoGenomics said its chief executive, Chris Smith, plans to retire April 1. The Fort Myers, Fla., oncology testing services company on Friday said Tony Zook, an independent board member since 2023, ...

Fort Myers-based oncology testing services company Neo Genomics announced Chris Smith will retire as CEO and board member ...

In a report released yesterday, Mark Massaro from BTIG maintained a Buy rating on NeoGenomics (NEO – Research Report), with a price target of ...

Shares of NeoGenomics tumbled after the oncology testing-services company said its chief executive, Chris Smith, will retire April 1. The stock fell 20%, to $14.91, in afternoon trading Friday. Shares ...

As a result of these changes, two senior roles – President of Research and Development, held by Martin Mackay, and Executive Vice President, Global Commercial, held by Tony Zook – have been ...

NeoGenomics (NEO) announced that Chris Smith will retire as CEO and board member effective April 1. Tony Zook, an independent board member ...

Tony Zook, an independent board member since 2023, will assume the role of CEO at that time. “Chris has provided exceptional leadership for NeoGenomics, joining the Company at a critical time ...